The DOI matches its Crossref record; 23 of the 28 references it cites were found in a registry or an index.
Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer
Open accessAbstract
Importance: Adjuvant chemotherapy in patients with stage III colon cancer prevents recurrence by eradicating minimal residual disease. However, which patients remain at high risk of recurrence after completing standard adjuvant treatment cannot currently be determined. Postsurgical circulating tumor DNA (ctDNA) analysis can detect minimal residual disease and is associated with recurrence in colorectal cancers. Objective: To determine whether serial postsurgical and postchemotherapy ctDNA analysis could provide a real-time indication of adjuvant therapy efficacy in stage III colon cancer. Design, Setting, and Participants: This multicenter, Australian, population-based cohort biomarker study recruited 100 consecutive patients with newly diagnosed stage III colon cancer planned for 24 weeks of adjuvant chemotherapy from November 1, 2014, through May 31, 2017. Patients with another malignant neoplasm diagnosed within the last 3 years were excluded. Median duration of follow-up was 28.9 months (range, 11.6-46.4 months). Physicians were blinded to ctDNA results. Data were analyzed from December 10, 2018, through June 23, 2019. Exposures: Serial plasma samples were collected after surgery and after chemotherapy. Somatic mutations in individual patients' tumors were identified via massively parallel sequencing of 15 genes commonly mutated in colorectal cancer. Personalized assays were designed to quantify ctDNA. Main Outcomes and Measures: Detection of ctDNA and recurrence-free interval (RFI). Results: After 4 exclusions, 96 eligible patients were eligible; median patient age was 64 years (range, 26-82 years); 49 (51%) were men. At least 1 somatic mutation was identified in the tumor tissue of all 96 evaluable patients. Circulating tumor DNA was detectable in 20 of 96 (21%) postsurgical samples and was associated with inferior recurrence-free survival (hazard ratio [HR], 3.8; 95% CI, 2.4-21.0; P < .001). Circulating tumor DNA was detectable in 15 of 88 (17%) postchemotherapy samples. The estimated 3-year RFI was 30% when ctDNA was detectable after chemotherapy and 77% when ctDNA was undetectable (HR, 6.8; 95% CI, 11.0-157.0; P < .001). Postsurgical ctDNA status remained independently associated with RFI after adjusting for known clinicopathologic risk factors (HR, 7.5; 95% CI, 3.5-16.1; P < .001). Conclusions and Relevance: Results suggest that ctDNA analysis after surgery is a promising prognostic marker in stage III colon cancer. Postchemotherapy ctDNA analysis may define a patient subset that remains at high risk of recurrence despite completing standard adjuvant treatment. This high-risk population presents a unique opportunity to explore additional therapeutic approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is a growing body of data demonstrating numerous clinical applications for ctDNA in adults with solid tumors, ranging from prognostication and evaluation of minimal residual disease (MRD) to detection of targetable alterations.7–12”
From Clinical Liquid Biopsy Testing for Detection of Actionable Genomic Alterations in Children and Young Adults With Advanced Solid Tumors on the GAIN Study (2026) · cites this paper as [11]
In the citing paper
“A salient example of the well-established relationship between ctDNA burden and disease status in adult solid tumors is the use of ctDNA for MRD detection and monitoring for recurrence in colorectal cancers.10–12”
From Clinical Liquid Biopsy Testing for Detection of Actionable Genomic Alterations in Children and Young Adults With Advanced Solid Tumors on the GAIN Study (2026) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Self-citationOxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J. M., Hickish, T., Topham, C., Zaninelli, M., Clingan, P. R., Bridgewater, J. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032709 · Cited by 3,694
Circulating mutant DNA to assess tumor dynamics
Diehl, F., Schmidt, K., Choti, M. A., Romans, K. E., Goodman, S. N., Li, M., Thornton, K. A., Agrawal, N., Sokoll, L. J., Szabo, S., et al. (2008) · Nature Medicine · doi:10.1038/nm.1789 · Cited by 2,746
Self-citationLevamisole and Fluorouracil for Adjuvant Therapy of Resected Colon Carcinoma
Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Goodman, P. J., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., Glick, J. H., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002083220602 · Cited by 2,261
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C. W., Modlin, L. A., Liu, C. L., Neal, J. W., Wakelee, H. A., Merritt, R. E., et al. (2014) · Nature Medicine · doi:10.1038/nm.3519 · Cited by 2,220
Tie, J., Wang, Y., Tomasetti, C., Li, L., Springer, S., Kinde, I., Silliman, N., Tacey, M., Wong, H.-L., Christie, M., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6219 · Cited by 1,492
Self-citationMutation tracking in circulating tumor DNA predicts relapse in early breast cancer
García-Murillas, I., Schiavon, G., Weigelt, B., Ng, C. K. Y., Hrebien, S., Cutts, R. J., Cheang, M. C. U., Osin, P., Nerurkar, A. Y., Kozarewa, I., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aab0021 · Cited by 1,174
Detection and quantification of rare mutations with massively parallel sequencing
Kinde, I., Wu, J., Papadopoulos, N., Kinzler, K. W., & Vogelstein, B. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105422108 · Cited by 1,144
Self-citationChaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H., Azad, T. D., Khodadoust, M. S., Esfahani, M. S., Liu, C. L., Zhou, L., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0716 · Cited by 1,105
Research works printed but not linked: 1
- Song, 2008, A semiparametric approach for the covariate specific ROC curve with survival outcome., Stat Sin, 947
Cited by
Sorted by citations
Items 101–200 of 690
Sfakianos, J. P., Basu, A., Laliotis, G., Cumarasamy, S., Rich, J. M., Kommalapati, A., Glover, M. J., Mahmood, T., Tillu, N., Hoimes, C. J., et al. (2024) · European Urology Oncology · doi:10.1016/j.euo.2024.07.001 · Cited by 48
Sullivan, B. G., Lo, A., Yu, J., Gonda, A., Dehkordi‐Vakil, F., Dayyani, F., & Senthil, M. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-12399-y · Cited by 47
Liquid biopsies for residual disease and recurrence
Wan, J. C. M., Mughal, T. I., Razavi, P., Dawson, S., Moss, E. L., Govindan, R., Tan, I. B., Yap, Y. S., Robinson, W. A., Morris, C. D., et al. (2021) · Med · doi:10.1016/j.medj.2021.11.001 · Cited by 48
Self-citationKuang, P., Li, N., Liu, Z., Sun, T., Wang, S.-Q., Hu, J., Ou, W., & Wang, S.-Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.595650 · Cited by 44
Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer
Conforti, F., Pala, L., Bagnardi, V., Pas, T. M. D., Colleoni, M. A., Buyse, M. E., Hortobágyi, G. N., Gianni, L., Winer, E. P., Loibl, S., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.3755 · Cited by 46
Chen, H., & Zhou, Q. (2023) · Oncology Reports · doi:10.3892/or.2023.8543 · Cited by 44
Sweeney, C. J., Petry, R., Xu, C., Childress, M. A., He, J., Fabrizio, D. A., Gjoerup, O. V., Morley, S., Catlett, T. S., Assaf, Z. J. F., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1096 · Cited by 44
The Role of Liquid Biopsy in Hepatocellular Carcinoma Prognostication
Labgaa, I., Villanueva, A., Dormond, O., Demartines, N., & Melloul, E. (2021) · Cancers · doi:10.3390/cancers13040659 · Cited by 46
CSCO guidelines for colorectal cancer version 2022: Updates and discussions
Yuan, Z., Weng, S., Ye, C., Hu, H., Zhang, S., & Yuan, Y. (2022) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2022.02.01 · Cited by 43
Newhook, T. E., Overman, M. J., Chun, Y. S., Dasari, A. N., Tzeng, C.-W. D., Cao, H. S. T., Raymond, V. M., Parseghian, C. M., Johnson, B., Nishioka, Y., et al. (2022) · Annals of Surgery · doi:10.1097/sla.0000000000005461 · Cited by 43
Postoperative tumor treatment strategies: From basic research to clinical therapy
Xiao, M., Wang, L., Tang, Q., Yang, Q., Yang, X., Zhu, G., Lei, L., & Li, S. (2024) · Open Research (University of Surrey) · doi:10.1002/viw.20230117 · Cited by 42
Erve, I. V. ’., Medina, J. E., Leal, A., Papp, E., Phallen, J. A., Adleff, V., Chiao, E. J., Arun, A. S., Bolhuis, K., Simmons, J. K., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2538 · Cited by 47
Cell-Free DNA as a Prognostic Biomarker for Monitoring Muscle-Invasive Bladder Cancer
Carrasco, R., Ingelmo‐Torres, M., Gómez, A., Trullás, R., Roldán, F. L., Ajami, T., Moreno, D., Rodríguez‐Carunchio, L., Alcaraz, A., Izquierdo, L., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911732 · Cited by 42
Liver transplantation in metastatic colorectal cancer: are we ready for it?
Ros, J., Salvà, F., Dopazo, C., López-Valbuena, D., Gonzalez, N. S., Baraibar, I., Charco, R., Tabernero, J. M., & Élez, E. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02213-1 · Cited by 40
State-of-the-Art Management of Colorectal Cancer: Treatment Advances and Innovation
Pathak, P., Chan, G. H. J., Deming, D. A., & Chee, C. E. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_438466 · Cited by 43
Liu, Z., Lu, T., Li, J., Wang, L., Xu, K., Dang, Q., Guo, C., Liu, L., Jiao, D., Sun, Z., et al. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02070-z · Cited by 39
Morris, V. K., Overman, M. J., Lam, M., Parseghian, C. M., Johnson, B., Dasari, A., Raghav, K., Kee, B. K., Huey, R., Wolff, R. A., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0194 · Cited by 38
Advances in novel strategies for isolation, characterization, and analysis of CTCs and ctDNA
Naei, V. Y., Bordhan, P., Mirakhorli, F., Khorrami, M., Shrestha, J., Nazari, H., Kulasinghe, A., & Warkiani, M. E. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231192401 · Cited by 38
Strategic approaches in oral squamous cell carcinoma diagnostics using liquid biopsy
Kinane, D. F., Gabert, J., Xynopoulos, G., & Guzeldemir-Akcakanat, E. (2024) · Periodontology 2000 · doi:10.1111/prd.12567 · Cited by 38
Manca, P., Corallo, S., Lonardi, S., Fucà, G., Busico, A., Leone, A. G., Corti, F., Antoniotti, C., Procaccio, L., Smiroldo, V., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01591-8 · Cited by 38
Slater, S., Bryant, A., Chen, H.-C., Begum, R., Rana, I., Aresu, M., Peckitt, C., Zhitkov, O., Lazaro-Alcausi, R., Borja, V., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-10699-4 · Cited by 37
Liquid biopsy: paving a new avenue for cancer research
Kurma, K., Eslami‐S, Z., Alix‐Panabières, C., & Cayrefourcq, L. (2024) · Cell Adhesion & Migration · doi:10.1080/19336918.2024.2395807 · Cited by 40
Negro, S., Pulvirenti, A., Trento, C., Indraccolo, S., Ferrari, S., Scarpa, M., Urso, E. D. L., Bergamo, F., Pucciarelli, S., Deidda, S., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062486 · Cited by 37
He, Y., Ma, X., Chen, K., Liu, F., Cai, S., Han‐Zhang, H., Hou, T., Xiang, J., & Peng, J. (2020) · Cancer Management and Research · doi:10.2147/cmar.s240869 · Cited by 37
Clinical implementation and current advancement of blood liquid biopsy in cancer
Watanabe, K., Nakamura, Y., & Low, S. (2021) · Journal of Human Genetics · doi:10.1038/s10038-021-00939-5 · Cited by 37
Ryoo, S., Heo, S., Lim, Y., Lee, W., Cho, S. H., Ahn, J., Kang, J., Kim, S. Y., Kim, H., Bang, D., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02300-3 · Cited by 35
Ma, D.-N., Gao, X., Wang, L., Yin, H., Feng, L.-H., & Zhu, Y. (2025) · Biomarker Research · doi:10.1186/s40364-025-00796-w · Cited by 35
Circulating tumor DNA in colorectal cancer: opportunities and challenges.
Bi, F., Wang, Q., Dong, Q., Wang, Y., Zhang, L., & Zhang, J. (2020) · PubMed Central · Cited by 35
Self-citationLu, Y., Wu, C., Yang, Y., Chen, X., Ge, F., Wang, J., & Deng, J. (2022) · Biomaterials Science · doi:10.1039/d1bm01596f · Cited by 35
Nakano, K., Koh, Y., Yamamichi, G., Yumiba, S., Tomiyama, E., Matsushita, M., Hayashi, Y., Wang, C., Ishizuya, Y., Yamamoto, Y., et al. (2022) · Cancer Science · doi:10.1111/cas.15334 · Cited by 34
The ASPREE Healthy Ageing Biobank: Methodology and participant characteristics
Parker, E. J., Orchard, S. G., Gilbert, T., Phung, J., Owen, A. J., Lockett, T. J., Nelson, M. R., Reid, C. M., Tonkin, A. M., Abhayaratna, W. P., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0294743 · Cited by 35
Self-citationAssociation of post-operative ctDNA detection with outcomes of patients with early breast cancers
Cutts, R. J., Ulrich, L., Beaney, M., Robert, M., Coakley, M. F., Bunce, C., Walsh-Crestani, G., Hrebien, S., Kalashnikova, E. V., Wu, H.-T., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103687 · Cited by 34
Comprehensive Review of Biomarkers for the Treatment of Locally Advanced Colon Cancer
Chuang, J., Tsai, H., Chen, P.-J., Chang, T., Su, W., Yeh, Y., Huang, C., & Wang, J. (2022) · Cells · doi:10.3390/cells11233744 · Cited by 34
Verzè, M., Pluchino, M., Leonetti, A., Corianò, M., Bonatti, F., Armillotta, M. P., Perrone, F., Casali, M., Minari, R., & Tiseo, M. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-390 · Cited by 36
A Micro-Costing Framework for Circulating Tumor DNA Testing in Dutch Clinical Practice
Kramer, A., Schuuring, E. M. D., Vessies, D. C. L., van der Leest, P., Geerlings, M. J., Rozendal, P., Lanfermeijer, M., Linders, T. C., van Kempen, L. C. L. T., Fijneman, R. J. A., et al. (2022) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2022.10.004 · Cited by 33
Catteruccia, N., Willingale-Theune, J., Bunke, D., Prior, R., Masters, C. L., Crisanti, A., & Beyreuther, K. T. (1990) · Europe PMC (PubMed Central) · Cited by 33
Dong, Q., Chen, C., Hu, Y., Zhang, W., Yang, X., Qi, Y., Zhu, C., Chen, X., Shen, X., & Ji, W. (2023) · Cancer Biology & Therapy · doi:10.1080/15384047.2023.2274123 · Cited by 35
Hashimoto, T., Nakamura, Y., Oki, E., Kobayashi, S., Yuda, J., Shibuki, T., Bando, H., & Yoshino, T. (2024) · International Journal of Clinical Oncology · doi:10.1007/s10147-024-02493-4 · Cited by 32
Martín-Arana, J., Gimeno-Valiente, F., Henriksen, T. V., García-Micó, B., Martínez-Castedo, B., Gambardella, V., Martínez‐Ciarpaglini, C., Lucas, B. P.-D., Huerta, M., Camblor, D. G., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-00960-z · Cited by 36
To, Y. H., Degeling, K., Kosmider, S., Wong, R., Lee, M., Dunn, C., Gard, G., Jalali, A., Wong, V., IJzerman, M. J., et al. (2021) · PharmacoEconomics · doi:10.1007/s40273-021-01047-0 · Cited by 32
Self-citationctDNA to Guide Adjuvant Therapy in Localized Colorectal Cancer (CRC)
Masfarré, L., Vidal, J., Fernández‐Rodríguez, C., & Montagut, C. O. (2021) · Cancers · doi:10.3390/cancers13122869 · Cited by 33
The Provocative Roles of Platelets in Liver Disease and Cancer
Marie, P. K., Fowlkes, N. W., Afshar‐Kharghan, V., Martch, S. L., Sorokin, A. V., Shen, J. P., Morris, V. K., Dasari, A. N., You, N., Sood, A. K., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.643815 · Cited by 32
Li, Y., Mo, S., Zhang, L., Ma, X., Hu, X., Huang, D., Lu, B., Luo, C., Peng, H., Cai, S., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.04.010 · Cited by 32
Wang, Y., Fan, X., Bao, H., Xia, F., Wan, J., Shen, L., Wang, Y., Zhang, H., Wei, Y., Wu, X., et al. (2022) · Clinical Chemistry · doi:10.1093/clinchem/hvac173 · Cited by 32
Self-citationLongitudinal Glioma Monitoring via Cerebrospinal Fluid Cell-Free DNA
Riviere-Cazaux, C., Dong, X., Mo, W., Kumar, R., Dai, C., Carlstrom, L. P., Munoz-Casabella, A., Ghadimi, K., Nesvick, C. L., Andersen, K. M., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1814 · Cited by 33
Chakrabarti, S., Kasi, A., Parikh, A. R., & Mahipal, A. (2022) · Cancers · doi:10.3390/cancers14133078 · Cited by 32
Applications of Liquid Biopsy for Surgical Patients With Cancer
Mahuron, K. M., & Fong, Y. (2023) · JAMA Surgery · doi:10.1001/jamasurg.2023.5394 · Cited by 31
Hao, M., Wang, K., Ding, Y., Li, H., Liu, Y., & Ding, L. (2022) · European journal of medical research · doi:10.1186/s40001-022-00759-z · Cited by 30
Marmorino, F., Prisciandaro, M., Giordano, M., Ortolan, E., Crucitta, S., Manca, P., Antoniotti, C., Valenti, M., Danesi, R., Conca, V., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.22.00244 · Cited by 30
Circulating tumor DNA methylation: a promising clinical tool for cancer diagnosis and management
Wang, B., Wang, M., Lin, Y., Zhao, J., Gu, H., & Li, X. (2024) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2023-1327 · Cited by 29
Ococks, E., Sharma, S., Ng, A. W. T., Aleshin, A. A., Fitzgerald, R. C., & Smyth, E. C. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.07.011 · Cited by 29
Schraa, S. J., van Rooijen, K. L., Koopman, M., Vink, G. R., & Fijneman, R. J. A. (2022) · Cancers · doi:10.3390/cancers14092218 · Cited by 29
Dawood, Z. S., Alaimo, L., Lima, H. A., Moazzam, Z., Shaikh, C. F., Ahmed, A. S., Munir, M. M., Endo, Y., & Pawlik, T. M. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-12641-7 · Cited by 29
Hofste, L. S. M., Geerlings, M. J., von Rhein, D. T., Rütten, H., Westenberg, A. H., Weiss, M. M., Gilissen, C., Hofste, T. G. J., van der Post, R. S., Klarenbeek, B. R., et al. (2023) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2023.01.026 · Cited by 29
Circulating tumor DNA in clinical trials for solid tumors: Challenges and current applications
Parisi, C., Tagliamento, M., Belcaid, L., Aldea, M. D., Bayle, A., Remon-Masip, J., Italiano, A., Planchard, D., Besse, B., & Barlési, F. (2023) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2023.100007 · Cited by 28
Madlener, S., Stepien, N. M., Senfter, D., Mayr, L., Laemmerer, A., Hedrich, C., Baumgartner, A., Lötsch-Gojo, D., Štěrba, J., Pokorná, P., et al. (2025) · Acta Neuropathologica · doi:10.1007/s00401-024-02842-7 · Cited by 28
Tian, X., Ge, D., Zhang, F., Zhang, B., Bai, W., Xu, X., Li, Z., Cao, Y., Li, P., Zou, K., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33362 · Cited by 28
Gong, J., Hendifar, A. E., Gangi, A., Zaghiyan, K. N., Atkins, K. M., Nasseri, Y. Y., Murrell, Z. A., Figueiredo, J. C., Salvy, S., Haile, R. W., et al. (2021) · Cancers · doi:10.3390/cancers13184547 · Cited by 28
Personalized Cancer Monitoring Assay for the Detection of ctDNA in Patients with Solid Tumors
Zhao, J., Reuther, J., Scozzaro, K., Hawley, M., Metzger, E., Emery, M., Chen, I., Barbosa, M., Johnson, L., O’Connor, A., et al. (2023) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-023-00670-1 · Cited by 29
Zou, H., Liu, W., Wang, X., Wang, Y., Wang, C., Qiu, C., Liu, H., Shan, D., Xie, T., Huang, W., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008450 · Cited by 27
Self-citationMeasurable residual disease (MRD)-testing in haematological and solid cancers
Chen, J., Gale, R. P., Hu, Y., Wen, Y., Wang, T., & Zhang, W. (2024) · Leukemia · doi:10.1038/s41375-024-02252-4 · Cited by 27
Casas‐Arozamena, C., Vilar, A., Cueva, J. F., Arias, E., Sampayo, V., Díaz, E., Oltra, S. S., Moiola, C. P., Cabrera, S., Cortegoso, A., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03158-w · Cited by 27
Sastre‐Garau, X., & Harlé, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.528957 · Cited by 27
Cirmena, G., Dameri, M., Ravera, F., Fregatti, P., Ballestrero, A., & Zoppoli, G. M. (2021) · Cancers · doi:10.3390/cancers13143460 · Cited by 29
BRAF-mutated colorectal adenocarcinomas: Pathological heterogeneity and clinical implications
Angerilli, V., Sabella, G., Centonze, G., Lonardi, S., Bergamo, F., Mangogna, A., Pietrantonio, F., Fassan, M., & Milione, M. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103647 · Cited by 27
Bent, A. H., Raghavan, S. A., Dasari, A. N., & Kopetz, S. (2022) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2022.03.004 · Cited by 27
Tumor‐associated macrophages and risk of recurrence in stage III colorectal cancer
Cavalleri, T., Greco, L., Rubbino, F., Hamada, T., Quaranta, M., Grizzi, F., Sauta, E., Craviotto, V., Bossi, P., Vetrano, S., et al. (2022) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.267 · Cited by 27
Yang, R., Wu, T., Yu, J., Cai, X., Li, G., Li, X., Huang, W., Zhang, Y., Wang, Y., Yang, X., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1182299 · Cited by 27
Self-citationLi, Y., Xu, J., Hu, X., Chen, Y., Liu, F., Chen, Y. F., Ma, X., Dong, Q., Sun, L., Mo, S., et al. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001236 · Cited by 27
Yu, J., Liao, L., Xiao, B., Zhang, X., Wu, A., Cheng, Y., Tang, J., Wu, J., Kong, L.-H., Han, K., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.7096 · Cited by 27
Circulating Tumor DNA Testing for Minimal Residual Disease and Its Application in Colorectal Cancer
Abidoye, O., Ahn, D. H., Borad, M. J., Wu, C., Bekaii‐Saab, T., Chakrabarti, S., & Sonbol, M. B. (2025) · Cells · doi:10.3390/cells14030161 · Cited by 26
Koessler, T., Paradiso, V., Piscuoglio, S., Nienhold, R., Ho, L. K. F., Christinat, Y., Terracciano, L., Cathomas, G., WICKI, A. N., McKee, T., et al. (2020) · Laboratory Investigation · doi:10.1038/s41374-020-0459-7 · Cited by 26
Conca, V., Ciracì, P., Boccaccio, C., Minelli, A., Antoniotti, C., & Cremolini, C. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102735 · Cited by 26
Galot, R., & Machiels, J. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101992 · Cited by 28
Dhiman, A., Kothary, V., Witmer, H. D. D., Bregio, C., Sood, D., Ong, C. T., Polite, B., Eng, O. S., Shergill, A., & Turaga, K. K. (2023) · Annals of Surgery · doi:10.1097/sla.0000000000005856 · Cited by 25
Parikh, A. R., Chee, B. H., Tsai, J., Rich, T. A., Price, K. S., Patel, S. A., Zhang, L., Ibrahim, F., Esquivel, M., Seventer, E. E. V., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3660 · Cited by 25
Wang, H., Gao, Y., Vafaei, S., Yu, Q., Zhang, J., & Wang, L. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.12.015 · Cited by 25
Utility of Cell-Free DNA Detection in Transplant Oncology
Reddy, T. P., Esmail, A., Chang, J. C., Ghobrial, R. M., & Abdelrahim, M. (2022) · Cancers · doi:10.3390/cancers14030743 · Cited by 25
Vaidya, A. M., Ayat, N. R., Buford, M., Wang, H., Shankardass, A., Zhao, Y., Gilmore, H. L., Wang, Z., & Lu, Z. (2020) · Theranostics · doi:10.7150/thno.47448 · Cited by 25
Novel Methylated DNA Markers in the Surveillance of Colorectal Cancer Recurrence
Xie, H., Mahoney, D. W., Foote, P. H., Burger, K. N., Doering, K. A., Taylor, W. R., Then, S. S., Cao, X., McGlinch, M. C., Berger, C. K., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2589 · Cited by 25
Taı̈eb, J., Souglakos, J., Boukovinas, I., Falcoz, A., Pagès, F., Messaritakis, I., Bennouna, J., Artru, P., Louvet, C., Lepère, C., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco.24.00648 · Cited by 26
Donato, S. D., Vignoli, A., Biagioni, C., Malorni, L., Mori, E., Tenori, L., Calamai, V., Parnofiello, A., Pierro, G. D., Migliaccio, I., et al. (2021) · Cancers · doi:10.3390/cancers13112762 · Cited by 25
Role of Circulating Tumor DNA in Gastrointestinal Cancers: Current Knowledge and Perspectives
Moati, É., Taly, V., Garinet, S., Didelot, A., Taı̈eb, J., Laurent‐Puig, P., & Zaanan, A. (2021) · Cancers · doi:10.3390/cancers13194743 · Cited by 25
Molecular testing for colorectal cancer: Clinical applications
Имянитов, Е. Н., & Kuligina, E. S. (2021) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v13.i10.1288 · Cited by 26
Nakamura, Y., Yokoyama, S., Matsuda, K., Tamura, K., Mitani, Y., Iwamoto, H., Mizumoto, Y., Murakami, D., Kitahata, Y., & Yamaue, H. (2021) · Scientific Reports · doi:10.1038/s41598-020-79909-4 · Cited by 24
Wang, R. Y., Zhao, A., Cao, N., Li, Z., Zhang, G., & Liu, F. (2020) · International Journal of Colorectal Disease · doi:10.1007/s00384-020-03667-y · Cited by 23
Use of Circulating Cell-Free DNA to Guide Precision Medicine in Patients with Colorectal Cancer
Morris, V. K., & Strickler, J. H. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-070119-120448 · Cited by 23
Wang, F., Lu, S., Cao, D., Qian, J., Li, C., Zhang, R., Wang, F., Wu, M., Liu, Y., Pan, Z., et al. (2023) · OncoImmunology · doi:10.1080/2162402x.2022.2161167 · Cited by 23
Self-citationMinimal Residual Disease in Colorectal Cancer: Are We Finding the Needle in a Haystack?
Jacome, A. A. D. A., & Johnson, B. (2023) · Cells · doi:10.3390/cells12071068 · Cited by 25
Epigenetic liquid biopsies for minimal residual disease, what’s around the corner?
Johnston, A. D., Ross, J. P., Ma, C., Fung, K. Y. C., & Locke, W. J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1103797 · Cited by 23
Yang, Y., Lü, Y., Tan, H. S., Bai, M., Wang, X., Ge, S., Ning, T., Zhang, L., Duan, J., Sun, Y., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-10863-w · Cited by 24
Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma
Huang, A., Zhang, X., & Zhou, J. (2021) · Biomarker Research · doi:10.1186/s40364-021-00348-y · Cited by 23
Zullo, L., Filippiadis, D. K., Hendriks, L. E. L., Portik, D., Spicer, J. D., Wistuba, I. I., & Besse, B. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00642-1 · Cited by 23
Camblor, D. G., Martínez-Castedo, B., Martín-Arana, J., Gimeno-Valiente, F., García-Micó, B., Martinez, F. M., Seguí, V., García-Bartolomé, M., González, D., Guimera, A., et al. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.103066 · Cited by 23
Zhao, L., Jiang, L., Liu, Y., Wang, X., Song, J., Sun, Y., Bai, Y., Dong, X. R., Sun, L., Wu, J., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.793 · Cited by 22
Copy Number Variations as Determinants of Colorectal Tumor Progression in Liquid Biopsies
Debattista, J., Grech, L., Scerri, C. A., & Grech, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021738 · Cited by 22
Iams, W. T., Kopparapu, P., Yan, Y., Muterspaugh, A., Zhao, Z., Chen, H., Cann, C., York, S. J., Horn, L., Ancell, K. K., et al. (2020) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2020.100024 · Cited by 22
Gimeno-Valiente, F., Martín-Arana, J., Tébar-Martínez, R., Gambardella, V., Martínez‐Ciarpaglini, C., García-Micó, B., Martínez-Castedo, B., Lucas, B. P.-D., García-Bartolomé, M., Seguí, V., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.102051 · Cited by 21
Frydendahl, A., Rasmussen, M. H., Jensen, S. Ø., Henriksen, T. V., Demuth, C., Diekema, M. H., Ditzel, H. J., Wen, S. W. C., Pedersen, J. S., Dyrskjøt, L., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084252 · Cited by 21
Szeto, S., Kytölä, S. I., Erkan, E. P., Ahtiainen, M., Mecklin, J., Kuopio, T., Sallinen, V. J., Lepistö, A., Koskenvuo, L. E., Renkonen‐Sinisalo, L., et al. (2025) · Cancer Medicine · doi:10.1002/cam4.70943 · Cited by 23
Metadata
- Authors
- Tie, J., Cohen, J. D., Wang, Y., Christie, M., Simons, K., Lee, M., Wong, R., Kosmider, S., Ananda, S., McKendrick, J., Lee, B., Cho, J. H., Faragher, I., Jones, I. T., Ptak, J., Schaeffer, M. J., Silliman, N., Dobbyn, L., Li, L., Tomasetti, C., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., & Gibbs, P.
- Affiliations
- The University of Melbourne (AU)
- Johns Hopkins University (US)
- The Royal Melbourne Hospital (AU)
- Walter and Eliza Hall Institute of Medical Research (AU)
- Western Health (AU)
- Eastern Health (AU)
- Division of Biostatistics & Bioinformatics, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland
- Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University School of Medicine, Baltimore, Maryland
- Corresponding author
- Tie, Jeanne
- ORCID
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2019-12-01
- Volume
- 5
- Issue
- 12
- Pages
- 1710
- ISSN
- 2374-2437 (ISSN-L)
- PMC
- PMC6802034
- OpenAlex
- W2980567593
- Cited by
- 668
- References
- 28
- Citations by year
- 2026: 76 · 2025: 91 · 2024: 104 · 2023: 124 · 2022: 107 · 2021: 102 · 2020: 57 · 2019: 6
- FWCI
- 21.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (P50CA062924)
- National Institute of General Medical Sciences (T32GM136577)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- circulating tumor DNA, stage III colon cancer, adjuvant chemotherapy, recurrence risk, minimal residual disease, recurrence-free interval, somatic mutations, liquid biopsy, predictive biomarkers, treatment response monitoring, recurrent colorectal cancer, recurrence-free survival, prognostic factors
- MeSH terms
- Circulating Tumor DNA, Adult, Aged, Aged, 80 and over, Australia, Colonic Neoplasms, Female, Humans, Male, Middle Aged, Mutation, Neoplasm Staging, Prognosis, Risk Factors, Biomarkers, Tumor, Treatment Outcome, Chemotherapy, Adjuvant, Neoplasm, Residual, Disease-Free Survival, Precision Medicine, High-Throughput Nucleotide Sequencing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
